Logotype for Bridgepoint Group plc

Bridgepoint Group (BPT) Trading update summary

Event summary combining transcript, slides, and related documents.

Logotype for Bridgepoint Group plc

Trading update summary

27 Oct, 2026

Performance and guidance

  • FY2026 PRE expected at 37%-39% of total income; medium-term PRE guidance from 2027 raised to 25%-30%; EBITDA margin guidance ~60% in 2026/27.

  • EBITDA guidance upgraded on exceptional ECP V performance; its gross MOIC exceeded 3x at June and is expected to exceed 4x at Q3, including a material ProEnergy valuation increase.

  • If ProEnergy remains at its Q3 valuation, 2026 PRE is expected to rise by ~$185m versus current consensus; further valuation upside could lift the outlook.

  • Management fee growth guidance is 13%-16% on a rolling three-year basis; expenses expected to rise at a high-single-digit rate in 2026 and mid-single-digit rates from 2027.

Cash generation and shareholder distributions

  • Projected 2026-30 cash receipts total £2.4bn: £1.3bn from PRE and £1.1bn from co-investments, versus ~£500m in 2021-25.

  • From FY2027, ordinary dividends target 40%-45% of EPS and will be paid quarterly.

  • Total capital returns target 40%-60% of Cash from Profits over five years to 2030, using ordinary dividends and additional dividends or buybacks as appropriate.

  • FY2026 dividend per share rebased from ~10p to 15p, subject to shareholder approval.

  • Transition dividends comprise a 4.8p interim, 5p Q3 second interim payable November 12, and intended 5.2p final dividend, subject to approval.

Fundraising and transactions

  • The €28bn mid-2024–2026 fundraising target was reached early; more than €30bn expected by year-end 2026, including €16bn raised in 2026; over a third of new flagship-fund capital came from new investors.

  • BE VIII raised €7.8bn, is expected to reach its €8.65bn hard cap and be fully allocated later in 2026, and has been fee-paying since June 9, 2026.

  • ECP VI closed at $8.1bn; BDL IV closed at €5.1bn, up 76% from BDL III; CLO X and XI priced successfully and CLO I reset.

  • KARE shareholder and fund-investor approvals received; completion expected January 4, 2027. Post-Kayne AUM expected at ~$125bn, with ~50% in the U.S. and ~50% in real assets.

  • Deployment: BE VIII 13%, BDC 49%, ECP VI 25% and KAREP VII 54%; up to 17 funds may be in market next year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Bridgepoint Group